[Testis germ cell tumours: which chemotherapy, for which patients?]

Area of Science:

• Oncology
• Urology

Background:

• Germ cell tumors of the testis are a curable malignancy.
• Two primary pathological subtypes exist: seminoma and non-seminoma.
• Disease staging includes localized (testis-limited) and advanced disease categories.

Purpose of the Study:

• To outline current treatment strategies for testicular germ cell tumors.
• To differentiate management approaches based on pathological subtype and disease stage.
• To detail chemotherapy regimens and the role of surgery in treatment.

Main Methods:

• Classification of advanced disease prognosis based on serum tumor markers and metastatic site.
• First-line chemotherapy regimens include bleomycin, etoposide, and cisplatin (BEP).
• Treatment adaptation based on prognostic factors, disease stage, and tumor subtype (seminoma vs. non-seminoma).

Main Results:

• Good prognostic factor patients receive three cycles of BEP; poor-risk patients receive four cycles.
• Non-seminoma management involves risk-adapted chemotherapy followed by surgical resection of residual disease.
• Stage I non-seminoma patients may receive two cycles of BEP; Stage I seminoma patients may receive one cycle of carboplatin.
• Advanced seminoma treatment involves chemotherapy followed by observation or surgical resection.
• Salvage chemotherapy regimens include ifosfamide, cisplatin, and either vinblastine or paclitaxel.

Conclusions:

• Testicular germ cell tumors are highly curable with risk-adapted treatment strategies.
• Chemotherapy combinations like BEP are central to first-line treatment.
• Surgical management plays a crucial role in non-seminoma and selected seminoma cases.
• Salvage chemotherapy offers options for refractory or relapsed disease.